non-holder here doing some DD: anyone has thoughts on the Ph 2 efficacy data for proteinuria comparing to the CSL Vifor data for sparsentan? DMX200 looks inferior to me and if sparsentan had issues meeting the primary endpoint in a Ph 3 why would DMX200 succeed?
non-holder here doing some DD: anyone has thoughts on the Ph 2...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $184.1M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.5¢ | 32.5¢ | $360.9K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 368307 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 1553 | 1 |
View Market Depth
| Last trade - 11.01am 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
33.5¢ |
Change
-0.005 ( 1.82 %) |
||||
| Open | High | Low | Volume | ||
| 34.0¢ | 34.0¢ | 33.0¢ | 920096 | ||
| Last updated 11.19am 15/05/2024 ? | |||||
| DXB (ASX) Chart |